Shield Therapeutics PLC

Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019.

''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're in a good place''.

''We have to convert that into a deal but we believe we have every prospect of doing that''.

''The approval in the US is great ...it should be extremely attractive to a significant number of partners and gives us a great deal of confidence that we can get a deal done''.

Quick facts: Shield Therapeutics PLC

Price: £1.83

Market: LSE
Market Cap: £214.46 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield looking to exploit 'significant' market opportunity after US approval...

Shield Therapeutics PLC's (LON:STX) Carl Sterritt sat down with Proactive London's Andrew Scott following US regulatory sign-off for their iron deficiency treatment. The Food & Drug Administration has given broad label approval to Feraccru, which will be marketed as Accrufer in...

3 weeks, 2 days ago

2 min read